Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors

Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors

20.5.2019 – Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau for the treatment of neurodegenerative diseases, today announces the appointment of Dr Eric Yuen to its Board of Directors.

read the complete information on Asceneuron website